Anmeldung erfolgt in Kürze...
Details werden geladen...
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) | The Manil...
MIAMI, May 08, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that a constructive Type C meeting with the U.S. Food and Drug Administration (FDA or Agency) was held in late March, with the FDA providing their meeting summary in late April, to discuss the ongoing development of laromestrocel (LOMECEL-B®), a proprietary, scalable, allogeneic, investigational cellular therapy currently being evaluated in a Phase 2b clinical trial (ELPIS II) for hypoplastic left heart syndrome (HLHS). Top-line results from the randomized, controlled Phase 2b ELPIS II clinical trial are anticipated in August 2026.
Ähnliche Seiten
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) () | aktiencheck.de
https://www.aktiencheck.de/news/Artikel-Longeveron_Announces_FDA_Grants_Type_C_Meeting_Ahead_of_Data_Readout_for_Pivotal_Phase_2_Clinical_Trial_ELPIS_II_Evaluating_Treatment_for_Hypoplastic_Left_Heart_Syndrome_HLHS-19402617
InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren's Syndrome in China | The Manila Times
https://www.manilatimes.net/2026/05/08/tmt-newswire/globenewswire/innocare-announces-approval-of-a-phase-ii-clinical-trial-of-tyk2-inhibitor-icp-488-for-sjogrens-syndrome-in-china/2339167
Aelis Farma announces the successful start of the recruitment of the Phase 2B clinical trial with AEF0217 for the treatment of behavioral and cognitive impairments of people with Down syndrome (Trisom...
https://www.finanznachrichten.de/nachrichten-2026-03/68002996-aelis-farma-announces-the-successful-start-of-the-recruitment-of-the-phase-2b-clinical-trial-with-aef0217-for-the-treatment-of-behavioral-and-cognitiv-004.htmTheriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma | The Manila Times
https://www.manilatimes.net/2026/03/23/tmt-newswire/globenewswire/theriva-biologics-announces-positive-end-of-phase-2-meeting-with-us-fda-regarding-the-design-of-a-phase-3-trial-of-vcn-01-in-metastatic-pancreatic-ductal-adenocarcinoma/2305479Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis | The ...
https://www.manilatimes.net/2026/03/23/tmt-newswire/globenewswire/quality-longevity-company-enlivex-receives-investigational-new-drug-ind-clearance-from-the-fda-for-phase-2b-trial-of-allocetra-in-age-related-primary-moderate-to-severe-knee-osteoarthritis/2305475